• Canaccord Genuity sets a price target of $33 for NYSE:PHR, indicating a potential increase of approximately 64%.
• Phreesia reports solid earnings with two consecutive quarters close to breakeven, signaling a path to profitability.
• The stock experienced a decline of approximately 0.86%, with fluctuations between $19.40 and $21.24.

Phreesia, Inc. (NYSE:PHR) is a healthcare technology company that provides a patient intake management platform. The platform helps healthcare providers streamline the patient intake process, improve patient engagement, and enhance operational efficiency. Phreesia competes with other healthcare technology companies like Cerner Corporation and Allscripts Healthcare Solutions.

On December 9, 2025, Richard Close from Canaccord Genuity set a price target of $33 for PHR. At that time, PHR was trading at $20.12, suggesting a potential increase of approximately 64%. Despite this optimistic outlook, Phreesia's stock experienced a decline, reflecting a decrease of approximately 0.86% or $0.175, with the stock fluctuating between $19.40 and $21.24.

Phreesia recently reported solid earnings, achieving two consecutive quarters close to breakeven. This progress indicates the company's path to profitability. However, the market reacted negatively, leading to a drop in the stock price. Investors are closely watching whether Phreesia's journey towards profitability will gain momentum following these near-breakeven quarters.

The company's market capitalization is approximately $1.21 billion, with a trading volume of 2,961,387 shares on the NYSE. Over the past year, PHR has reached a high of $32.76 and a low of $18.55. Despite the recent decline, the price target set by Canaccord Genuity suggests potential growth for the stock.